FAP and neoplasm: Meanwhile, we found that a single administration of 200 to 500 μCi of [177Lu]Lu-DOTA-FD3 satisfactorily suppressed the growth of tumors of small volumes at the onset of the therapies, producing durable responses in both HT1080-FAP and T3M-4 tumor models at the endpoint of efficacy monitoring.